Press Release

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients